In summary, both studies together (see ref. 49) support a model whereby PHD3 levels in tumour cells are flexibly regulated by various growth-promoting and growth inhibitory signals from the tumour microenvironment through the regulation of EGFR signalling. Here, EGLN3 is linked to neoplasm.